ReviewThe American journal of case reports2026
A 17-Year-Old Male Adolescent With Refractory Crohn's Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence.
Mohammad Alhashemi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.